2001
Glial Cell Line-Derived Neurotrophic Factor (GDNF) Gene Delivery Protects Dopaminergic Terminals from Degeneration
Connor B, Kozlowski D, Unnerstall J, Elsworth J, Tillerson J, Schallert T, Bohn M. Glial Cell Line-Derived Neurotrophic Factor (GDNF) Gene Delivery Protects Dopaminergic Terminals from Degeneration. Experimental Neurology 2001, 169: 83-95. PMID: 11312561, DOI: 10.1006/exnr.2001.7638.Peer-Reviewed Original ResearchMeSH KeywordsAgingAnimalsAutoradiographyCarrier ProteinsCocaineCorpus StriatumDisease Models, AnimalDopamineDopamine Plasma Membrane Transport ProteinsGenetic TherapyGenetic VectorsGlial Cell Line-Derived Neurotrophic FactorMaleMembrane GlycoproteinsMembrane Transport ProteinsMicroinjectionsMotor ActivityNerve Growth FactorsNerve Tissue ProteinsNeuronsNeurotransmitter AgentsOxidopamineParkinson Disease, SecondaryPresynaptic TerminalsRatsRats, Inbred F344RNA, MessengerSubstantia NigraTyrosine 3-MonooxygenaseConceptsGlial cell line-derived neurotrophic factorGDNF gene deliverySubstantia nigraDA terminalsDA neuronsNeuronal sproutingGlial cell line-derived neurotrophic factor (GDNF) gene deliveryAmphetamine-induced rotational asymmetryLine-derived neurotrophic factorUnilateral intrastriatal injectionAged rat brainDopaminergic neuronal functionTyrosine hydroxylase mRNADA transporter ligandsNigrostriatal functionStriatal injectionAxonal sproutingDopaminergic terminalsIntrastriatal injectionStriatal denervationDenervated striatumWeeks postlesionNeurotrophic factorNigrostriatal axonsPartial lesions
1999
Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment
Elsworth J, Taylor J, Sladek J, Collier T, Redmond D, Roth R. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment. Neuroscience 1999, 95: 399-408. PMID: 10658619, DOI: 10.1016/s0306-4522(99)00437-6.Peer-Reviewed Original ResearchConceptsHomovanillic acid/dopamine ratioMPTP treatmentStriatal dopamine levelsDopamine levelsDopamine lossDopamine depletionDopamine ratioStriatal subregionsNucleus accumbensCaudate nucleusDopamine concentrationsOne-yearSeverity categoriesDopamine neuron integrityVentromedial caudate nucleusStriatal dopamine lossHomovanillic acid concentrationsStriatal dopaminergic functionMarked increaseNormal motor performancePaucity of dataMetabolic activityNon-human primatesParkinsonian disabilityTetrahydropyridine (MPTP) model
1997
(S)-(-)-HA-966, a gamma-hydroxybutyrate-like agent, prevents enhanced mesocorticolimbic dopamine metabolism and behavioral correlates of restraint stress, conditioned fear and cocaine sensitization.
Morrow B, Lee E, Taylor J, Elsworth J, Nye H, Roth R. (S)-(-)-HA-966, a gamma-hydroxybutyrate-like agent, prevents enhanced mesocorticolimbic dopamine metabolism and behavioral correlates of restraint stress, conditioned fear and cocaine sensitization. Journal Of Pharmacology And Experimental Therapeutics 1997, 283: 712-21. PMID: 9353390.Peer-Reviewed Original ResearchConceptsHA-966Dopamine metabolismMedial prefrontal cortexCocaine sensitizationNucleus accumbensHigh doseAcute cocaine-induced locomotionPrefrontal cortexGABAB receptor bindingCocaine-induced locomotionGamma-aminobutyric acidStress-induced increaseFear-inducing behaviorDopamine utilizationGABAB receptorsRestraint stressControl ratsLocomotor sensitizationDopaminergic neurotransmissionShell subdivisionBaclofen bindingCortical membranesPositive enantiomerWeight gainReceptor binding
1994
Preexposure to, but Not Cotreatment with, the Neurotensin Antagonist SR 48692 Delays the Development of Cocaine Sensitization
Horger B, Taylor J, Elsworth J, Roth R. Preexposure to, but Not Cotreatment with, the Neurotensin Antagonist SR 48692 Delays the Development of Cocaine Sensitization. Neuropsychopharmacology 1994, 11: 215-222. PMID: 7865101, DOI: 10.1038/sj.npp.1380108.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCocaineMaleMotor ActivityPyrazolesQuinolinesRatsRats, Sprague-DawleyReceptors, NeurotensinTime FactorsConceptsCocaine challenge injectionSR 48692Role of neurotensinDevelopment of sensitizationEffects of cocaineCocaine sensitizationChallenge injectionDay drug-free periodMale Sprague-Dawley ratsCocaine-induced locomotor activityDrug-free periodSprague-Dawley ratsCocaine-induced locomotor activationCocaine-induced activityDrug-free daysEffects of cotreatmentPreexposure injectionsDaily administrationLocomotor activationCocaine testLocomotor deficitsLocomotor activityActivity countsChronic preexposureCocaine testing
1992
Unilateral Transplantation of Human Fetal Mesencephalic Tissue into the Caudate Nucleus of Patients with Parkinson's Disease
Spencer D, Robbins R, Naftolin F, Marek K, Vollmer T, Leranth C, Roth R, Price L, Gjedde A, Bunney B, Sass K, Elsworth J, Kier E, Makuch R, Hoffer P, Redmond D. Unilateral Transplantation of Human Fetal Mesencephalic Tissue into the Caudate Nucleus of Patients with Parkinson's Disease. New England Journal Of Medicine 1992, 327: 1541-1548. PMID: 1435880, DOI: 10.1056/nejm199211263272201.Peer-Reviewed Original ResearchMeSH KeywordsActivities of Daily LivingAdultAntiparkinson AgentsCaudate NucleusCryopreservationCyclosporineDopamineFemaleFetal Tissue TransplantationHomovanillic AcidHumansMagnetic Resonance ImagingMaleMesencephalonMiddle AgedMotor ActivityParkinson DiseasePutamenStereotaxic TechniquesTomography, Emission-ComputedConceptsCase patientsParkinson's diseaseMesencephalic tissueCaudate nucleusHuman fetal ventral mesencephalic tissueFetal ventral mesencephalic tissueHuman fetal mesencephalic tissueContinued disease progressionFetal dopaminergic neuronsFetal mesencephalic tissueVentral mesencephalic tissueSevere Parkinson's diseaseOptimal drug therapySigns of parkinsonismMidbrain dopamine neuronsPositron emission tomographyMonths of evaluationAntiparkinsonian medicationUnilateral transplantationDrug holidayMore medicationsStriatonigral degenerationNeurologic functionDopaminergic neuronsDrug therapy
1991
Grafting of fetal substantia nigra to striatum reverses behavioral deficits induced by MPTP in primates: a comparison with other types of grafts as controls
Taylor J, Elsworth J, Roth R, Sladek J, Collier T, Redmond D. Grafting of fetal substantia nigra to striatum reverses behavioral deficits induced by MPTP in primates: a comparison with other types of grafts as controls. Experimental Brain Research 1991, 85: 335-348. PMID: 1893983, DOI: 10.1007/bf00229411.Peer-Reviewed Original ResearchConceptsCaudate nucleusBehavioral deficitsHealthy behaviorsFetal substantia nigra cellsFetal substantia nigraIdiopathic Parkinson's diseasePoverty of movementType of graftDays/weekSubstantia nigra cellsTime of sacrificePre-treatment levelsSN cellsSpecific behavioral effectsMPTP treatmentMPTP toxicityParkinsonian signsSubstantia nigraControl subjectsInitiation of movementBrain sitesLimb tremorParkinson's diseaseControl animalsMPTP
1990
Cocaethylene inhibits uptake of dopamine and can reach high plasma concentrations following combined cocaine and ethanol use.
Jatlow P, Hearn W, Elsworth J, Roth R, Bradberry C, Taylor J. Cocaethylene inhibits uptake of dopamine and can reach high plasma concentrations following combined cocaine and ethanol use. NIDA Research Monograph 1990, 105: 572-3. PMID: 1876124.Peer-Reviewed Original Research
1987
Reversal of Parkinsonism by Fetal Nerve Cell Transplants in Primate Braina
SLADEK J, COLLIER T, HABER S, DEUTCH A, ELSWORTH J, ROTH R, REDMOND D. Reversal of Parkinsonism by Fetal Nerve Cell Transplants in Primate Braina. Annals Of The New York Academy Of Sciences 1987, 495: 641-657. PMID: 2886092, DOI: 10.1111/j.1749-6632.1987.tb23706.x.Peer-Reviewed Original Research